Fig. 6

Involvement of extracellular ATP on MUC5AC release in viral-infected NCI-H292 cells. a, b Effect of a pannexin channel inhibitor, carbenoxolone (CBX), on the release of extracellular ATP (a) and MUC5AC (b) in RV14-infected NCI-H292 cells. Cells were treated with 10 μM CBX or vehicle 1 h prior to RV 14 infection. Cells were infected with RV 14 for 90 min and the virus was removed and replaced with medium. After 24 h or 48 h incubation, supernatants were harvested and assayed. Supernatants were assessed for the concentration of extracellular ATP by fluorometric assay and MUC5AC release by ELISA. c Effect of a non-selective antagonist of P2R, suramin, on MUC5AC release in RV 14-infected cells. Cells were treated with 10 μM suramin or vehicle 30 min prior to RV 14 infection. After 48 h RV 14 infection, the supernatants were harvested and assayed for MUC5AC release by ELISA. The data are expressed as the means ± SEM for three to four separate experiments. **p < 0.01, ***p < 0.001 compared with the values of vehicle-treated control